Microscopic-Observation Drug-Susceptibility Assay for the Diagnosis of TB

BACKGROUND New diagnostic tools are urgently needed to interrupt the transmission of tuberculosis and multidrug-resistant tuberculosis. Rapid, sensitive detection of tuberculosis and multidrug-resistant tuberculosis in sputum has been demonstrated in proof-of-principle studies of the microscopic-observation drug-susceptibility (MODS) assay, in which broth cultures are examined microscopically to detect characteristic growth. METHODS In an operational setting in Peru, we investigated the performance of the MODS assay for culture and drug-susceptibility testing in three target groups: unselected patients with suspected tuberculosis, prescreened patients at high risk for tuberculosis or multidrug-resistant tuberculosis, and unselected hospitalized patients infected with the human immunodeficiency virus. We compared the MODS assay head-to-head with two reference methods: automated mycobacterial culture and culture on Löwenstein-Jensen medium with the proportion method. RESULTS Of 3760 sputum samples, 401 (10.7%) yielded cultures positive for Mycobacterium tuberculosis. Sensitivity of detection was 97.8% for MODS culture, 89.0% for automated mycobacterial culture, and 84.0% for Löwenstein-Jensen culture (P<0.001); the median time to culture positivity was 7 days, 13 days, and 26 days, respectively (P<0.001), and the median time to the results of susceptibility tests was 7 days, 22 days, and 68 days, respectively. The incremental benefit of a second MODS culture was minimal, particularly in patients at high risk for tuberculosis or multidrug-resistant tuberculosis. Agreement between MODS and the reference standard for susceptibility was 100% for rifampin, 97% for isoniazid, 99% for rifampin and isoniazid (combined results for multidrug resistance), 95% for ethambutol, and 92% for streptomycin (kappa values, 1.0, 0.89, 0.93, 0.71, and 0.72, respectively). CONCLUSIONS A single MODS culture of a sputum sample offers more rapid and sensitive detection of tuberculosis and multidrug-resistant tuberculosis than the existing gold-standard methods used.

[1]  J. Palomino,et al.  Evaluation of the polymerase chain reaction for the detection of Mycobacterium tuberculosis. , 2000, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[2]  M. Perkins New diagnostic tools for tuberculosis. , 2000, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[3]  C. Dolea,et al.  World Health Organization , 1949, International Organization.

[4]  L. Collins,et al.  Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium , 1997, Antimicrobial agents and chemotherapy.

[5]  B. Robinson-Dunn,et al.  Multicenter Evaluation of Ethambutol Susceptibility Testing of Mycobacterium tuberculosis by Agar Proportion and Radiometric Methods , 2002, Journal of Clinical Microbiology.

[6]  M. Patarroyo,et al.  Multiprimer PCR system for differential identification of mycobacteria in clinical samples , 1996, Journal of clinical microbiology.

[7]  A. R. Escombe,et al.  Infrequent MODS TB culture cross-contamination in a high-burden resource-poor setting. , 2006, Diagnostic microbiology and infectious disease.

[8]  T. Bodmer,et al.  Multicenter Evaluation of the MB/BACT System for Susceptibility Testing of Mycobacterium tuberculosis , 2004, Journal of Clinical Microbiology.

[9]  M. Lourenço,et al.  Comparison of Flow Cytometric and Alamar Blue Tests with the Proportional Method for Testing Susceptibility of Mycobacterium tuberculosis to Rifampin and Isoniazid , 2004, Journal of Clinical Microbiology.

[10]  M. Perkins,et al.  Diagnostic testing in the control of tuberculosis. , 2002, Bulletin of the World Health Organization.

[11]  A R Feinstein,et al.  Use of methodological standards in diagnostic test research. Getting better but still not good. , 1995, JAMA.

[12]  W. Yew,et al.  Comparison of MB/BacT system and agar proportion method in drug susceptibility testing of Mycobacterium tuberculosis. , 2001, Diagnostic microbiology and infectious disease.

[13]  A. Barreto,et al.  Evaluation of indirect susceptibility testing of Mycobacterium tuberculosis to the first- and second-line, and alternative drugs by the newer MB/BacT system. , 2003, Memorias do Instituto Oswaldo Cruz.

[14]  R. Cole,et al.  Clinical evaluation of a rapid immunochromatographic assay based on the 38 kDa antigen of Mycobacterium tuberculosis on patients with pulmonary tuberculosis in China. , 1996, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[15]  R. Fontana,et al.  Reliability of the MB/BacT System for Testing Susceptibility of Mycobacterium tuberculosis Complex Isolates to Antituberculous Drugs , 2000, Journal of Clinical Microbiology.

[16]  David Moher,et al.  Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. , 2004, Family practice.

[17]  Paul Farmer,et al.  Community-based treatment of multidrug-resistant tuberculosis in Lima, Peru: 7 years of experience. , 2004, Social science & medicine.

[18]  A. Feinstein,et al.  Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. , 1978, The New England journal of medicine.

[19]  I. Khan,et al.  Microplate nitrate reductase assay versus Alamar Blue assay for MIC determination of Mycobacterium tuberculosis. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[20]  C B Begg,et al.  Biases in the assessment of diagnostic tests. , 1987, Statistics in medicine.

[21]  R. O'brien,et al.  Evaluation of the MycoDot test in patients with suspected tuberculosis in a field setting in Tanzania. , 1999, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[22]  D. Berg,et al.  Rapid, Efficient Detection and Drug Susceptibility Testing of Mycobacterium tuberculosis in Sputum by Microscopic Observation of Broth Cultures , 2000, Journal of Clinical Microbiology.

[23]  Donna Neuberg,et al.  Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. , 2003, The New England journal of medicine.

[24]  P. Kissinger,et al.  Improved Recovery of Mycobacterium tuberculosis From Children Using the Microscopic Observation Drug Susceptibility Method , 2006, Pediatrics.

[25]  R. Chaisson,et al.  Performance of the Microscopic Observation Drug Susceptibility Assay in Drug Susceptibility Testing for Mycobacterium tuberculosis , 2002, Journal of Clinical Microbiology.

[26]  D. Rennie,et al.  The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. , 2003, Annals of internal medicine.

[27]  E. Bouza,et al.  Evaluation of the MB/BacT Mycobacterium Detection System for Susceptibility Testing of Mycobacterium tuberculosis , 2000, Journal of Clinical Microbiology.

[28]  A. Khomenko,et al.  Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. , 2000, JAMA.

[29]  M. Sakatani,et al.  [A cooperative clinical study on the evaluation of an antibody detection test kit (MycoDot Test) for mycobacterial infections. Cooperative Study Group for MycoDot Test]. , 1997, Kekkaku : [Tuberculosis].

[30]  C. Evans,et al.  Microscopic Observation Drug Susceptibility Assay, a Rapid, Reliable Diagnostic Test for Multidrug-Resistant Tuberculosis Suitable for Use in Resource-Poor Settings , 2004, Journal of Clinical Microbiology.

[31]  E. Tortoli,et al.  Comparison of Mycobacterium tuberculosis susceptibility testing performed with BACTEC 460TB (Becton Dickinson) and MB/BacT (Organon Teknika) systems. , 2000, Diagnostic microbiology and infectious disease.

[32]  B. Hamasur,et al.  Diagnostic evaluation of urinary lipoarabinomannan at an Ethiopian tuberculosis centre. , 2001, Scandinavian journal of infectious diseases.

[33]  R. McNerney,et al.  Guidelines for establishing trials of new tests to diagnose tuberculosis in endemic countries. , 2004, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[34]  J. Bayona,et al.  Identifying early treatment failure on category I therapy for pulmonary tuberculosis in Lima Ciudad, Peru. , 2004, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[35]  P. Fujiwara,et al.  Tuberculosis bacteriology--priorities and indications in high prevalence countries: position of the technical staff of the Tuberculosis Division of the International Union Against Tuberculosis and Lung Disease. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[36]  Robert H. Gilman,et al.  Rapid, Low-Technology MIC Determination with Clinical Mycobacterium tuberculosis Isolates by Using the Microplate Alamar Blue Assay , 1998, Journal of Clinical Microbiology.

[37]  O'Brien Rj,et al.  Evaluation of the MycoDot test in patients with suspected tuberculosis in a field setting in Tanzania. , 1999 .

[38]  R. Chaisson,et al.  The potential impact of enhanced diagnostic techniques for tuberculosis driven by HIV: a mathematical model , 2006, AIDS.

[39]  M. Perkins,et al.  More rigour needed in trials of new diagnostic agents for tuberculosis , 2000, The Lancet.